As of Summer 2018, principals of the firm appear to have moved on. Visionary Pharmaceuticals, Inc., a biotechnology company, had been developing small molecule therapies for unmet medical needs in cancer and inflammation, and specializes in translating chemical entities to the clinic and delivers nuclear receptor modulators to treat rheumatoid arthritis, multiple sclerosis, psoriasis, COPD, and cancer. The firm has created an innovative drug discovery engine utilizing novel proprietary technology (BindingSIGHTs) to focus on nuclear hormone receptors, which represent 15% of all drugs approved in the US. Along with the MANIFOLD virtual compound library, this technology provides advanced structural biology capabilities to optimize the development of drug candidates. Visionary Pharmaceuticals drug discovery portfolio includes RORγt and SGK1. RORγt is an important target in both cancer and autoimmune diseases including inflammatory bowel disease, arthritis, multiple sclerosis, psoriasis and more than 70 other autoimmune diseases. RORγt is also a novel target for colorectal cancer
